Treatment with STS protects pancreatic cells in three ways, including a reduction in ROS production, inhibiting the expression of thioredoxin-binding protein 2, a redox protein associated with diabetes that promotes apoptosis, and increasing GSH content, all of which reduce the damage caused by oxidative stress [72–74]. Here, TXNIP is linked to diabetes mellitus.